Product Development
INTER-K's R&D is focused on the development and rationalization of a number of peptide-based compounds that have anti-cancer activity. These compounds are:
- Water soluble
- Effective against a broad range of cancers including breast, bowel, lung, prostate, ovary and melanoma.
- Easily synthesised
INTER-K utilises its own scientific expertise and that of selected contract research organisations for R&D.
Products
INTRODUCING A NOVEL ANTI-CANCER PEPTIDE FROM INTER-K IK248
INTER-K has discovered a new cell-signaling pathway describing a physical interaction between integrin 
and a member of the intracellular growth promoting MAP kinase family, ERK2. Integrin is highly expressed at the invading edge of various cancers.
INTER-K's lead compound, designated IK248, is a non-naturally occurring new chemical entity designed to inhibit this pathway. IK248 is effective against bowel, breast, prostate and stomach cancers in vitro;
MTT Cell Proliferation Assays:
Cell Lines Challenged with IK248 for 48 Hrs in serum
IK248 inhibits activation of ERK in HT29 colon cancer cells
IK248 inhibits colon cancer growth in mice
In vitro growth inhibition of HT29 colon cancer cells by IK248 present in mouse serum at various time points following i.v. administration of 15mg/kg modified IK248 into athymic mice 
Modified IK248 is much more effective in vitro against HT29 colon cancer cells than standard chemotherapy
IK248 and it's modified derivatives are non toxic when given intravenously to mice at relatively high concentrations, do not require a facilitator or carrier moiety to enter cells and are stable in serum.
Extension of pharmacokinetic and in vitro efficacy studies for a range of common tumor types are currently in progress.
INTER-K SEEKS TO ESTABLISH A SUITABLE PARTNERING ARRANGEMENT TO ENSURE THE ONGOING RAPID COMMERCIALIZATION OF ITS ANTI-CANCER TECHNOLOGY.
AN INDICATION OF THE NATURE AND SCOPE OF THE INFORMATION THAT CAN BE DISCLOSED UNDER A CONFIDENTIALITY AGREEMENT WILL BE PROVIDED TO INTERESTED PARTIES ON REQUEST.